Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo shows promise for Hard-to-Treat GI cancers

NCT ID NCT03929666

Completed Disease control Sponsor: Jazz Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested a new drug called zanidatamab (ZW25) combined with standard chemotherapy in 74 people with advanced HER2-positive cancers of the stomach, bile duct, or colon. The goal was to see if the combination is safe and shrinks tumors. Results will help decide if larger studies are warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Zanidatamab (ZW25) plus standard chemotherapy drugs
What this could lead to
If successful, this could point toward a more effective first-line treatment option for people with HER2-positive gastrointestinal cancers.
What could go wrong
This is a small, early-phase trial (Phase 2) with no control group, so results may not confirm real benefit. Side effects from combining multiple drugs could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms cholangiocarcinoma colorectal cancer colorectal neoplasm digestive system neoplasm Esophageal Neoplasms gastric neoplasm gastroesophageal adenocarcinoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-EXPRESSING GASTROINTESTINAL CANCERS, INCLUDING GASTROESOPHAGEAL ADENOCARCINOMA, BILIARY TRACT CANCER, AND COLORECTAL CANCER

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, 05505, South Korea

  • CECIM Biocinetic

    Santiago, 8320000, Chile

  • Centro Internacional de Estudios Clínicos

    Santiago, 8420383, Chile

  • Centro de Investigacion Clinica SAGA

    Santiago, 7500653, Chile

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

  • H. Lee Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California, 92663, United States

  • Icegclinic Research & Care

    Santiago, 8241479, Chile

  • Korea University Anam Hospital

    Seoul, 02841, South Korea

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Nebraska Methodist Hospital

    Omaha, Nebraska, 68114, United States

  • Princess Margaret Cancer Center

    Toronto, Ontario, M5G 2C1, Canada

  • Pusan National University

    Busan, 49241, South Korea

  • Sarah Cannon Research Institute

    Nashville, Tennessee, 37203, United States

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, 13620, South Korea

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • Severance Hospital

    Seoul, 03722, South Korea

  • The Cancer and Hematology Centers

    Grand Rapids, Michigan, 49503, United States

  • The Ottawa Hospital Cancer Centre

    Ottawa, Ontario, K1H 8L6, Canada

  • USC/Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

  • University of Chicago

    Chicago, Illinois, 60637, United States

  • Virginia Mason Medical Center

    Seattle, Washington, 98101, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.